Barclays
MRVI icon

Barclays’s Maravai LifeSciences MRVI Stock Holding History

Barclays’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$78.3K Sell
27,656
-144,625
-84% -$490K ﹤0.01% 4135
2025
Q4 		$560K Buy
172,281
+5,057
+3% +$17K ﹤0.01% 3775
2025
Q3 		$480K Sell
167,224
-47,661
-22% -$122K ﹤0.01% 3839
2025
Q2 		$518K Buy
214,885
+60,631
+39% +$127K ﹤0.01% 3742
2025
Q1 		$341K Sell
154,254
-53,038
-26% -$210K ﹤0.01% 3756
2024
Q4 		$1.13M Buy
207,292
+23,103
+13% +$149K ﹤0.01% 3296
2024
Q3 		$1.53M Buy
184,189
+143,184
+349% +$1.24M ﹤0.01% 3065
2024
Q2 		$294K Buy
41,005
+13,644
+50% +$118K ﹤0.01% 3352
2024
Q1 		$237K Buy
27,361
+3,384
+14% +$22.9K ﹤0.01% 4023
2023
Q4 		$157K Sell
23,977
-235
-1% -$1.52K ﹤0.01% 4509
2023
Q3 		$242K Buy
24,212
+486
+2% +$5.34K ﹤0.01% 3208
2023
Q2 		$295K Sell
23,726
-15,010
-39% -$203K ﹤0.01% 3059
2023
Q1 		$543K Buy
38,736
+33,030
+579% +$474K ﹤0.01% 3213
2022
Q4 		$81.7K Sell
5,706
-4,891
-46% -$77K ﹤0.01% 4346
2022
Q3 		$270K Buy
10,597
+1,187
+13% +$29.8K ﹤0.01% 3043
2022
Q2 		$268K Buy
9,410
+4,519
+92% +$143K ﹤0.01% 3271
2022
Q1 		$172K Buy
+4,891
New +$164K ﹤0.01% 3510

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Barclays's MRVI Position: Q1 2026 in Review

Barclays reduced its Maravai LifeSciences (MRVI) stake by 84% in Q1 2026, selling an estimated $490K and leaving 27,656 shares worth $78.3K. The position accounts for ﹤0.01% of the portfolio, ranked #4135.

Barclays first reported a position in MRVI in Q1 2022 and has held it in 17 quarters since. The position peaked at $1.53M in Q3 2024. 158 funds tracked by Wall St. Rank hold MRVI as of Q1 2026.

  • Barclays held 27,656 shares of Maravai LifeSciences worth $78.3K as of Q1 2026.
  • Barclays sold 144,625 Maravai LifeSciences shares in Q1 2026, an estimated $490K.
  • Maravai LifeSciences made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4135 holding.
  • Barclays first reported a position in Maravai LifeSciences in Q1 2022 and has held it in 17 quarters since.
  • Barclays's Maravai LifeSciences position peaked at $1.53M in Q3 2024.
  • 158 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.